Evidence map›Paper›PMID 32877954›Full record

ArticleThrombosis and haemostasis2021

Monitoring DOACs with a Novel Dielectric Microsensor: A Clinical Study.

Debnath Maji, Aman Opneja, Michael A Suster, Kara L Bane, Brigid M Wilson, Pedram Mohseni, Evi X Stavrou

Abstract read
In one paragraph

Article in Thrombosis and haemostasis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. [Research on blood viscoelasticity detection based on electrowetting technology].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Debnath Maji *Department of Electrical, Computer, and Systems Engineering, Case Western Reserve University, Cleveland, Ohio, United States.
Aman Opneja *Hematology and Oncology Division, Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States.
Michael A SusterDepartment of Electrical, Computer, and Systems Engineering, Case Western Reserve University, Cleveland, Ohio, United States.
Kara L BaneDivision of Hematology-Oncology, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States.
Brigid M WilsonGeriatric Research Education and Clinical Center, Louis Stokes Cleveland Veterans Administration Medical Center, VA Northeast Ohio Healthcare System, Cleveland, Ohio, United States.
Pedram MohseniDepartment of Electrical, Computer, and Systems Engineering, Case Western Reserve University, Cleveland, Ohio, United States.
Evi X StavrouDivision of Hematology-Oncology, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States.ORCID 0000-0002-6075-7609

Funding

Targeted Abrogation of the FXII-uPAR-pAkt2 Axis in Neutrophils for Treatment of Chronic WoundsR01HL137695 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI STAVROU, EVI X. · 2019 to 2023
$2.0M
Treatment of Deep Vein Thrombosis via Targeted Inhibition of the FXII-uPAR-pAkt2 Axis in NeutrophilsI01BX003851 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI Evi X. Stavrou · 2020 to 2026
–
17GRNT33661005 American Heart Association Grant-in-Aid awardBLRD VA I01 BX003851NHLBI NIH HHS R01 HL137695
6 · The paper itself

Abstract

backgroundThere are acute settings where assessing the anticoagulant effect of direct oral anticoagulants (DOACs) can be useful. Due to variability among routine coagulation tests, there is an unmet need for an assay that detects DOAC effects within minutes in the laboratory or at the point of care.

methodsWe developed a novel dielectric microsensor, termed ClotChip, and previously showed that the time to reach peak permittivity (

resultsWe accrued 154 individuals: 50 healthy volunteers, 49 rivaroxaban patients, 47 apixaban, and 8 dabigatran patients. Blood samples underwent ClotChip measurements and plasma coagulation tests. Control mean

conclusionThis diagnostic study using samples from "real-world" DOAC patients supports that ClotChip exhibits high sensitivity at detecting DOAC anticoagulant effects in a disposable portable platform, using a miniscule amount of whole blood (<10 µL).

Indexed as

AgedAged, 80 and overBlood CoagulationBlood Coagulation TestsDabigatranDrug MonitoringEquipment DesignFactor Xa InhibitorsFemaleHumansMaleMiddle AgedPyrazolesPyridonesRivaroxabanapixabanDabigatranFactor Xa InhibitorsPyrazolesPyridonesRivaroxaban

Identifiers

PMID32877954
PMCPMC8379997

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.